# Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

> **NCT00878072** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 53 (actual)

## Conditions studied

- Herpes Labialis

## Interventions

- **DRUG:** Famciclovir

## Key facts

- **NCT ID:** NCT00878072
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-25
- **Primary completion:** 2010-06-02
- **Final completion:** 2010-06-02
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00878072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00878072, "Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00878072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*